Lumicitabine
- Generic Name
- Lumicitabine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C18H25ClFN3O6
- CAS Number
- 1445385-02-3
- Unique Ingredient Identifier
- BNW5PQ52G1
- Background
Lumicitabine is under investigation in clinical trial NCT03010059 (A Study to Assess the Relative Bioavailability of JNJ64041575 Administered as 2 Different New Concept Formulations (Oral Suspension and Tablet) Compared to Their Respective Current Formulations, and to Assess the Effect of Food on the Pharmacokinetics of the 2 New Concept Formulations).
- Associated Conditions
- -
- Associated Therapies
- -
Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Oral Lumicitabine Regimens in Hospitalized Adult Participants Infected With Human Metapneumovirus
- First Posted Date
- 2018-04-19
- Last Posted Date
- 2018-11-15
- Lead Sponsor
- Janssen Research & Development, LLC
- Registration Number
- NCT03502694
- Locations
- π«π·
HΓ΄pital Tenon, Paris, France
πΊπΈMemorialCare Research Miller Children's and Women's Hospital Long Beach, Long Beach, California, United States
πΊπΈLake Internal Medicine Associates, Eustis, Florida, United States
A Crossover Study to Assess the Drug-drug Interaction of Acid Reducing Agent(s) on the Pharmacokinetics of a Single Oral Dose of Lumicitabine (JNJ-64041575) in Healthy Adult Participants
- First Posted Date
- 2018-03-19
- Last Posted Date
- 2018-07-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 18
- Registration Number
- NCT03468777
- Locations
- π§πͺ
Clinical Pharmacology Unit, Merksem, Belgium
A Crossover Study to Assess the Effect of Intravenous Infusion of Piperacillin/Tazobactam on the Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) in Healthy Adult Participants
- First Posted Date
- 2018-02-22
- Last Posted Date
- 2018-06-07
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 18
- Registration Number
- NCT03441529
- Locations
- π§πͺ
Clinical Pharmacology Unit, Merksem, Belgium
A Long-term Follow-up Study to Evaluate the Impact of Lumicitabine on the Incidence of Asthma and/or Wheezing in Infants and Children With a History of Respiratory Syncytial Virus Infection
- Conditions
- Interventions
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2021-04-13
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 7
- Registration Number
- NCT03332459
- Locations
- π―π΅
National Hospital Organization Niigata National Hospital, Niigata, Japan
π―π΅Fukuyama City Hospital, Fukuyama, Japan
π―π΅National Hospital Organization Beppu Medical Center, Oita, Japan
A Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) Regimens in Hospitalized Infants and Children Aged 28 Days to 36 Months Infected With Respiratory Syncytial Virus
- Conditions
- Interventions
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2019-12-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 7
- Registration Number
- NCT03333317
- Locations
- π―π΅
Takatsuki General Hospital, Osaka, Japan
π―π΅Shikoku Medical Center for Children and Adults, Zentsuji, Japan
π΅π±Plejady Medical Center, Malopolska, Poland
Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine Regimens in Adult Participants Hospitalized With Respiratory Syncytial Virus
- Conditions
- Interventions
- First Posted Date
- 2016-10-17
- Last Posted Date
- 2019-12-24
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 49
- Registration Number
- NCT02935673
Study to Evaluate the Effect of ALS-008176 on Cardiac Repolarization Interval in Healthy Participants
- First Posted Date
- 2016-07-14
- Last Posted Date
- 2017-09-18
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 103
- Registration Number
- NCT02833831
A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus
- Conditions
- Interventions
- First Posted Date
- 2016-02-04
- Last Posted Date
- 2017-10-25
- Lead Sponsor
- Alios Biopharma Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT02673476
- Locations
- πΈπ¬
Raffles Hospital, Singapore, Singapore
πΊπΈSt Lucie Medical Center, Port Saint Lucie, Florida, United States
πΊπΈThe Research Center, Inc., Hialeah, Florida, United States
A Phase 1, Open-Label Study of the Absorption, Metabolism, Excretion and Absolute Bioavailability of ALS-008176
- Conditions
- Interventions
- First Posted Date
- 2014-09-04
- Last Posted Date
- 2017-10-31
- Lead Sponsor
- Alios Biopharma Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT02231671
- Locations
- π¬π§
Quotient Clinical, Nottingham, United Kingdom
A Study of ALS-008176 in Infants Hospitalized With RSV
- Conditions
- Interventions
- First Posted Date
- 2014-07-29
- Last Posted Date
- 2019-04-04
- Lead Sponsor
- Alios Biopharma Inc.
- Target Recruit Count
- 183
- Registration Number
- NCT02202356
- Locations
- πΊπΈ
The Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States
π¦πΊThe Canberra Hospital, Canberra, Australia
π¦πΊPrincess Margaret Hospital, Perth, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.